Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

Recruiting

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(4 sites)

France

Institut Curie, Paris, Paris

Centre Leon Berard, Lyon

Institut Godinot, Reims

Hopital Foch, Suresnes